New pill shows promise in slowing untreated leukemia
NCT ID NCT04075292
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests whether a targeted drug called acalabrutinib works better than a standard combination of chemotherapy (chlorambucil) and an antibody (rituximab) for people with untreated chronic lymphocytic leukemia (CLL). About 155 adults aged 65 or older (or younger with certain health issues) took part. The main goal was to see how long patients lived without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100191, China
-
Research Site
Changchun, 130021, China
-
Research Site
Changsha, 410013, China
-
Research Site
Changzhou, 272100, China
-
Research Site
Guangzhou, 510100, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Guiyang, 550004, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Hefei, 230001, China
-
Research Site
Hefei, 230031, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanjing, 210029, China
-
Research Site
Qingdao, 110016, China
-
Research Site
Shanghai, 200025, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Shanghai, 200050, China
-
Research Site
Shenyang, 110001, China
-
Research Site
Shijiazhuang, 050020, China
-
Research Site
Suzhou, 215006, China
-
Research Site
Taiyuan, 030001, China
-
Research Site
Tianjin, 300020, China
-
Research Site
Xuzhou, 221000, China
-
Research Site
Zhengzhou, 450008, China
-
Research Site
Zhengzhou, 450052, China
-
Research Site
Baguio City, 2600, Philippines
-
Research Site
Cebu, 6000, Philippines
-
Research Site
Davao City, 8000, Philippines
-
Research Site
Makati, 1229, Philippines
-
Research Site
Manila, 1000, Philippines
-
Research Site
Quezon City, 1112, Philippines
-
Research Site
Chiayi City, 613, Taiwan
-
Research Site
Hualien City, 97002, Taiwan
-
Research Site
Kaohsiung City, 833, Taiwan
-
Research Site
Taichung, 404, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Taipei, 11217, Taiwan
-
Research Site
Bangkok, 10330, Thailand
-
Research Site
Bangkok, 10400, Thailand
-
Research Site
Bangkok, 10700, Thailand
-
Research Site
Chiang Mai, 50200, Thailand
-
Research Site
Hat Yai, 90110, Thailand
-
Research Site
Khon Kaen, 40002, Thailand
-
Research Site
Hanoi, 100000, Vietnam
-
Research Site
Ho Chi Minh City, 700000, Vietnam
Conditions
Explore the condition pages connected to this study.